| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1609 | |
| Phytochemical name or plant extracts | Quercetin 3-O-β-d-mannuronpyranoside | |
| PMID | 33923148 | |
| Literature evidence | AME and compounds exerted similar or better antioxidant activity to ascorbic acid using DPPH, O2-, and NO inhibition methods. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Quercetin aglycone in the organic phase and mannuronic acid in the aqueous one (COPC) | |
| Source of phytochemicals or plant Extracts | Callistemon viminalis | |
| Geographical availability | New South Wales, Queensland | |
| Plant parts | Aerial parts | |
| Other cancers | Breast cancer, Liver cancer | |
| Target gene or protein | 5-LOX | |
| Gene or Protein evidence | All compounds occupied the 5-LOX active site and showed binding affinity greater than ascorbic acid or quercetin. | |
| Target pathways | The inhibition of 5-LOX could be a potential therapeutic pathway to treat and prevent cancer formation via blocking the oxidative and inflammatory pathways | |
| IC50 | 127.4 μM against MCF-7 | |
| Potency | The above-mentioned compounds may be a potential new antitumor and/or adjuvant treatment against liver and breast cancer. | |
| Cell line/ mice model | MCF-7, HepG2 | |
| Additional information | NA | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:914221-1 | |
| Safety | NA |